SCHEDULE 13G/A: Suvretta Capital Management and Affiliates Maintain Significant Stake in 89bio, Inc.

Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have filed an amended Schedule 13G, reporting continued beneficial ownership of 8.5% of 89bio, Inc.'s common stock as of December 31, 2024.

Summary

• Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in 89bio, Inc.
• As of December 31, 2024, Suvretta Capital Management, LLC and Aaron Cowen each beneficially own 10,202,696 shares, representing 8.5% of 89bio, Inc.'s common stock.
• Averill Master Fund, Ltd. beneficially owns 9,162,636 shares, representing 7.7% of 89bio, Inc.'s common stock.
• All reported securities are directly owned by advisory clients of Suvretta Capital Management, LLC, with Averill Master Fund, Ltd. being the only client identified as owning more than 5%.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of 89bio, Inc., other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: This is a neutral, routine ownership disclosure. The continued significant stake by an institutional investor could be seen as mildly positive, but the filing itself provides no new operational or financial information to significantly shift sentiment.

Positives

• A significant institutional investor, Suvretta Capital Management, LLC, and its affiliates maintain a substantial stake in 89bio, Inc., indicating continued confidence in the company.

Negatives

• No specific negative information regarding 89bio, Inc.'s operations or financial health was disclosed in this ownership filing.

Risks

• The filing includes a standard certification that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, mitigating immediate control-related risks from these specific filers.

Future Outlook

This Schedule 13G/A filing is an ownership disclosure and does not contain forward-looking statements or guidance regarding 89bio, Inc.'s future outlook.

Industry Context

This filing is a routine ownership disclosure and does not provide specific industry context or analysis.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership and confirms that the stake is passive, not intended to influence control.

Next Steps

• No specific future actions or milestones for 89bio, Inc. are mentioned in this ownership filing.

Key Dates

Keywords

89bio Inc., BBIO, Schedule 13G/A, SEC filing, beneficial ownership, institutional investor, Suvretta Capital Management, Averill Master Fund, Aaron Cowen, common stock